

Anti-CCR5/CD195 Antibody (Leronlimab)

Introduction

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimumab inhibits CCR-mediated HIV-1 virus and lung metastasis in mouse tumor models. Leronlimab can be used in the study of HIV nonalcoholic steatohepatitis (NASH) and cancer.

Product parameters

Alternative Names	HUPRO-140, PRO-140
Target Accession	P51681
Target	CCR5 / CD195
CAS number	674782-26-4
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CCR5 His EGFP HEK293 cells were stained with Anti-CCR5/CD195 Antibody (Leronlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.3073 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

